Danske Lægers Vaccinations Service Due Diligence
Run due diligence on Danske Lægers Vaccinations Service: check compliance and get alerts when suppliers or ownership change.
Denmark · owned by TopCo 40 IV-A Holding GmbH (Germany) · www.sikkerrejse.dk · 19 vendors
Danske Lægers Vaccinations Service (DLVS) is Denmark's largest provider of vaccinations, operating a nationwide network of 47 clinics staffed by approximately 350 doctors, nurses, and medical students. The company specialises in travel vaccinations, general vaccinations (influenza, HPV, COVID-19, etc.), blood tests, and corporate/school vaccination programmes. It is part of European LifeCare Group A/S.
Resilience scores
- Digital Sovereignty: 26
- Digital Resilience: 5
- Financial Resilience: 8
Technology vendors
- Google LLC — Technology — United States
- Meta Platforms, Inc. — Technology — United States
- Mobile Rocket Limited — United Kingdom
- and 16 more
Insights
Last updated 2026-11-13 · revision 2
19 direct vendors, 163 subvendors
Direct vendors by controlling owner country (sample)
- Denmark: 5
- India: 1
- United Kingdom: 2
Subvendors by controlling owner country (sample)
- Canada: 2
- Russia: 1
- United States: 123
Compliance
11 in-scope frameworks identified; showing 3.
Sundhedsloven — Evidence found
As a provider of healthcare services (vaccinations) in Denmark, the company is subject to the Danish Health Act.
Evidence: https://p4h.world/en/documents/the-health-service-act-of-denmark-2024/, https://www.bm.dk/media/7028/helbredsoplysningslov.pdf, https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/compliance-post-authorisation/good-distribution-practice, https://rimap.unhcr.org/node/60136, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-clinical-practice, https://paperguide.ai/research-glossary/good-clinical-practice/
EU GDP — No public evidence
The company distributes and stores vaccines, which are medicinal products. This activity falls under the scope of EU Good Distribution Practice guidelines.
SOC 2 (source) — No public evidence
A SOC 2 report would provide assurance to corporate clients and partners about the security, availability, and confidentiality of the systems used to process their data.
Financials
Three-year financials
- 2025: revenue DKK 573M, EBIT DKK 82.8M, equity DKK 235M
- 2024: revenue DKK 501M, EBIT DKK 62.2M, equity DKK 171M
- 2023: revenue DKK 244M, EBIT DKK 33.6M, equity DKK 123M
Financial Resilience Score: 8/10
Danske Lægers Vaccinations Service (CVR 10104653, operating under European LifeCare Group A/S) demonstrates strong financial resilience based on its filed FY2025 accounts. Revenue has more than doubled from DKK 244M in 2023 to DKK 573M in 2025, while EBIT margins have remained stable in the 12-15% range (14.5% in 2025), indicating that profitability has scaled alongside growth rather than being eroded by expansion costs. Equity has nearly doubled over two years from DKK 123M to DKK 235M, with net profit roughly equal to equity delta, implying retained earnings are funding growth with minimal dividend extraction — a solid capital cushion. The company benefits from recurring public-sector contracts (Danish regions' autumn vaccination tenders for flu and COVID-19), a diversified footprint of 44+ clinics plus mobile units across Denmark, and multiple revenue streams spanning seasonal public programmes, travel vaccinations (~200,000 Danes annually), corporate workplace vaccinations (1,700+ companies), and clinical research collaborations. Private equity backing (transitioned from Inflexion to Findos in 2025) provides access to institutional capital for continued buy-and-build strategy. Key risks include tender/contract concentration with Danish regions (loss of an autumn tender could abruptly cut turnover), post-COVID demand normalisation potentially decelerating the explosive 2023-2024 growth, heavy reliance on part-time seasonal clinicians (799 CVR headcount vs 236 FTE), and potential re-leveraging under new PE ownership. Reputational scrutiny of the 'Danske Lægers' branding (suggesting public-sector affiliation that does not exist) has also been raised in journalism.
Key strengths: Revenue more than doubled from DKK 244M (2023) to DKK 573M (2025), Stable EBIT margin of ~14% despite rapid scaling, Equity nearly doubled from DKK 123M to DKK 235M in two years, Recurring Danish regions' autumn vaccination tender contracts, 44+ clinics plus mobile units across Denmark, diversified revenue streams, Private equity backing (Findos, from Inflexion in 2025) for continued buy-and-build, Group operates 84 specialist clinics across DK, UK, NL, SE delivering ~3M vaccinations/year
Risk factors: Tender/contract concentration with Danish regions, Post-COVID normalisation could decelerate growth, Heavy reliance on part-time seasonal clinicians (workforce availability risk), PE ownership transition in 2025 may lead to re-leveraging, Reputational scrutiny of 'Danske Lægers' branding suggesting false public affiliation
Workforce by country
- Denmark: 236
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.